Search Results 2551-2560 of 12868 for immunosuppressant drugs
Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...
Integrative medicine combines complementary and alternative medicine (CAM) practices with conventional medicine.
... drugs approved on the basis of a surrogate endpoint by the FDA between January 2009 and December 2014. Twenty-five drugs received accelerated (provisional) ...
... drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal ...
The purpose of this study is to offer pre-approval drug access of iniparib combined with gemcitabine and carboplatin, in order to provide potential clinical ...
Durski JM, Weigel RJ, McDougall IR. Recombinant human thyrotropin (rh TSH) in the management of differentiated thyroid cancer. Nuclear Medicine Communications.
The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't approved by the U.S. Food and Drug Administration (FDA). However, ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.